Reduced IGFBP-1 Is Associated With Thickening of the Carotid Wall in Type 2 Diabetes
- Eeva S. Leinonen, MD1,
- Jukka T. Salonen, MD, PHD45,
- Riitta M. Salonen, MD, PHD4,
- Riitta A. Koistinen, PHD2,
- Pekka J. Leinonen, MD, PHD2,
- Seppo S. Sarna, PHD3 and
- Marja-Riitta Taskinen, MD, PHD1
- 1Department of Internal Medicine, Helsinki University Central Hospital, Helsinki, Finland
- 2Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
- 3Department of Public Health, University of Helsinki, Helsinki, Finland
- 4Research Institute of Public Health, University of Kuopio, Kuopio, Finland
- 5Inner Savo Health Center, Suonenjoki, Finland
Abstract
OBJECTIVE—The aim of the present study was to assess the role of the insulin-like growth factor (IGF) system and lipids in predicting the carotid intima-media thickness (IMT) in type 2 diabetes.
RESEARCH DESIGN AND METHODS—A total of 239 type 2 diabetic participants in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study (76 women) aged 50–75 years were examined before fenofibrate intervention. Patients underwent carotid ultrasonography for determination of IMT. IGF-I, IGF binding protein 1 (IGFBP-1), IGFBP-3, cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, apolipoprotein B (apoB), lipoprotein(a) (Lp(a)), glucose, HbA1c, and C-peptide were measured in fasting samples. Patients were divided in groups without (n = 168) and with (n = 71) clinical cardiovascular disease (CVD).
RESULTS—Partial correlations adjusted for age, sex, BMI, and diabetes duration showed an inverse association of IGFBP-1 with C-peptide (r = −0. 24, P = 0.018) and with maximal IMT (r = −0.42, P < 0.001), whereas IGF I and IGFBP-3 correlated positively with several risk-promoting lipid parameters. In linear regression analysis controlling for age, sex, BMI, diabetes duration, and presence or absence of oral antihyperglycemic or insulin medication, determinants of IMT were age, IGFBP-1, pulse pressure, Lp(a), diabetes duration, and insulin treatment. IGFBP-1 persisted in the model for subjects with CVD.
CONCLUSIONS—In summary, a decrease in IGFBP-1 is a marker of carotid IMT thickening in patients with type 2 diabetes.
- apoB, apolipoprotein B
- CB, carotid bulb
- CCA, common carotid artery
- CVD, cardiovascular disease
- FIELD, Fenofibrate Intervention and Event Lowering in Diabetes
- FW, far wall
- HOMA-IR, homeostasis model assessment of insulin resistance
- ICA, internal carotid artery
- IGF, insulin-like growth factor
- IGFBP, insulin-like growth factor binding protein
- IMT, intima-media thickness
- Lp(a), lipoprotein(a)
- Max IMT, maximal intima-media thickness
- OHA, oral antihyperglycemic agents
Footnotes
-
Address correspondence and reprint requests to Marja-Riitta Taskinen, Professor, Helsinki University Central Hospital, Department of Medicine, P.O. Box 340, Floor 11, Haartmaninkatu 4, 00029 HUS, Helsinki, Finland. E-mail: marja-riitta.taskinen{at}hus.fi.
Received for publication 20 January 2002 and accepted in revised form 29 June 2002.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
- DIABETES CARE
